Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced the presentation of positive new data from multiple ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

New Data Highlighting in vitro Potency Advantages for VIBATIV® (telavancin) Against Difficult-to-Treat MRSA and MSSA Pathogens Reported at ASM Microbe 2017June 5, 2017 8:30 AM